Strides Pharma Science receives USFDA warning letter for its Puducherry facility

Bs_logoImage
Capital Market
Last Updated : Jul 02 2019 | 12:05 PM IST
Strides Pharma Science has received a warning letter from USFDA relating to Puducherry facility.

Puducherry site currently produces 6 ANDAs which will not get impacted by the current development. However, the 10 ANDAs pending approval from the site will get deferred till the site is reclassified.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jul 02 2019 | 11:48 AM IST